Organo Therapeutics
OrganoTherapeutics is a drug development company that has pioneered the development of human patient-specific midbrain organoids, which are miniaturized, simplified versions of the human brain developed in the lab. There are currently no truly curative treatments for Parkinson’s disease available and no complete, patient-specific mid-brain organoids for developing treatments. Using their ‘mini-brain’ technology, OrganoTherapeutics has developed new small-molecule compounds that target neurodegeneration in Parkinson’s disease and can be used to develop other neurodegenerative treatments.